According to the new market research study of “Liposome Drug Delivery Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Product (Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B, Others); Technology (Stealth Liposome Technology, Non-PEGylated Liposome Technology, DepoFoam Liposome Technology, Lysolipid Thermally Sensitive Liposome (LTSL) Technology); Application (Fungal Diseases, Cancer Therapy, Pain Management, Viral Vaccines, Photodynamic Therapy); and Geography”, the market is expected to reach US$ 6,992.95 million by 2027 from US$ 3,594.41 million in 2019. The market is estimated to grow with a CAGR of 8.8% from 2020 to 2027. The report highlights trends prevailing in the global liposome drug delivery market and the factors driving market along with those that act as hindrances.
The liposome drug delivery market, by application, is segmented into fungal diseases, cancer therapy, pain management, viral vaccines, and photodynamic therapy. In 2019, the cancer therapy segment accounted for the largest market share of the global liposome drug delivery market. The liposome-based treatments have gained popularity to overcome the problems and side effects of the conventional chemotherapy treatment. Liposomal drugs have high encapsulation capacity and hence show a significant anticancer activity with decreased toxicity. Furthermore, drug delivery systems enhance the therapeutic index of anticancer agents and these biomolecules have a natural ability to target cancer cells. The aforementioned factors are likely to be responsible for the growth of the segment in the liposome drug delivery market.
Drugs and devices required for the drug delivery are required to undergo a thorough clinical development process in order to obtain FDA approval. The drug delivery product approval process involves Phase 1, 2, and 3. Costs can be analyzed on the basis of three circumstances—drugs that have been developed through approval, drugs still in development, and drugs that were terminated in development. The survey for new molecules and their integration or encapsulation in liposomes as nano-coating or other technologies also incur significant costs that may not be affordable to small and mid-sized pharmaceutical and biotechnology companies. Thus, the increasing cost for the development of liposomal drug delivery is expected to hamper the growth of the market to a certain extent.
Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.theinsightpartners.com/sample/TIPRE00010407/
- Takeda Pharmaceutical Company Limited
- Novartis AG
- Luye Pharma Group
- Ipsen Pharma
- CELSION, Inc.
- Gilead Sciences, Inc.
- Astellas Pharma, Inc.
- Johnson & Johnson Services, Inc.
- Acrotech Biopharma, Inc.
The liposome drug delivery market majorly consists of players such as Takeda Pharmaceutical Company Limited, Novartis AG, Luye Pharma Group, Ipsen Pharma, Celsion, Inc., Gilead Sciences, Inc., Astellas Pharma, Inc., Johnson & Johnson Services, Inc., and Acrotech Biopharma, Inc. The companies are focused toward the adoption of organic and inorganic strategies such as partnerships, agreements and expansion to sustain their position in the dynamic market. For instance, in June 2019, Pacira Pharmaceuticals entered into an agreement with Nuance, a Chinese pharmaceutical company, to advance the development and commercialization of Exparel (bupivacaine liposome injectable suspension) in China.
Partnerships, agreements, and acquisitions are the most commonly adopted strategies by companies to expand their footprints worldwide and meet the growing demand. The market players most commonly adopt these strategies to expand their geographic presence and product portfolio.
For instance, in April 2019, Ipsen Pharma completed its acquisition of global oncology assets from Merrimack Pharmaceuticals, Cambridge that focuses on ONIVYDE (irinotecan liposome injection) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
Purchase a copy of this research report @ https://www.theinsightpartners.com/buy/TIPRE00010407/
Global Liposome Drug Delivery Market – By Product
- Liposomal Doxorubicin
- Liposomal Paclitaxel
- Liposomal Amphotericin B
Global Liposome Drug Delivery Market – By Technology
- Stealth Liposome Technology
- Non-PEGylated Liposome Technology
- DepoFoam Liposome Technology
- Lysolipid Thermally Sensitive Liposome (LTSL) Technology
Global Liposome Drug Delivery Market – By Application
- Fungal Diseases
- Cancer Therapy
- Pain Management
- Viral Vaccines
- Photodynamic Therapy
Liposome Drug Delivery Market – By Geography
- North America
- Asia Pacific
- South Korea
- Middle East and Africa
- South Africa
- Saudi Arabia
- South and Central America
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.